PDCD1 and colorectal cancer: Specifically, individuals with MSI-H/dMMR colorectal cancer are often responsive to anti-PD-1/PD-L1 immunotherapy, making it a promising treatment option for this subgroup of patients, as it is currently approved for this group only [13].